인쇄하기
취소
|
AstraZeneca applied for an appeal to the nullification of patents related to substance and more in Korea, it was not able to get the rights back. It is analyzed the AstraZeneca’s strategy to take a favorable position in defending its patents through change of composition practically turned into a failure.
On the 9th, the Intellectual Property Tribunal made a decision to decline the appeal agai...